<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Russian Journal of Biotherapy</journal-id><journal-title-group><journal-title xml:lang="en">Russian Journal of Biotherapy</journal-title><trans-title-group xml:lang="ru"><trans-title>Российский биотерапевтический журнал</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1726-9784</issn><issn publication-format="electronic">1726-9792</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1553</article-id><article-id pub-id-type="doi">10.17650/1726-9784-2025-24-2-56-65</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>ORIGINAL REPORTS</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">Physical-chemical and thermal studies of solid dispersions of desloratadine</article-title><trans-title-group xml:lang="ru"><trans-title>Физико-химические и термические исследования твердых дисперсий дезлоратадина</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0123-9526</contrib-id><name-alternatives><name xml:lang="en"><surname>Polkovnikova</surname><given-names>Yu. A.</given-names></name><name xml:lang="ru"><surname>Полковникова</surname><given-names>Ю. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Yuliya A. Polkovnikova.</p><p>1 Universitetskaya pl., Voronezh 394018</p></bio><bio xml:lang="ru"><p>Полковникова Юлия Александровна.</p><p>394018 Воронеж, Университетская пл., 1</p></bio><email>juli-polk@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0000-6543-2531</contrib-id><name-alternatives><name xml:lang="en"><surname>Beginina</surname><given-names>D. D.</given-names></name><name xml:lang="ru"><surname>Бегинина</surname><given-names>Д. Д.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Daria D. Beginina.</p><p>1 Universitetskaya pl., Voronezh 394018</p></bio><bio xml:lang="ru"><p>394018 Воронеж, Университетская пл., 1</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5775-9884</contrib-id><name-alternatives><name xml:lang="en"><surname>Tulskaya</surname><given-names>U. A.</given-names></name><name xml:lang="ru"><surname>Тульская</surname><given-names>У. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Ulyana A. Tulskaya.</p><p>1 Universitetskaya pl., Voronezh 394018</p></bio><bio xml:lang="ru"><p>394018 Воронеж, Университетская пл., 1</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1939-253X</contrib-id><name-alternatives><name xml:lang="en"><surname>Lenshin</surname><given-names>A. S.</given-names></name><name xml:lang="ru"><surname>Леньшин</surname><given-names>А. С.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Alexandr S. Lenshin.</p><p>1 Universitetskaya pl., Voronezh 394018</p></bio><bio xml:lang="ru"><p>394018 Воронеж, Университетская пл., 1</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0005-4763-7038</contrib-id><name-alternatives><name xml:lang="en"><surname>Golovina</surname><given-names>A. A.</given-names></name><name xml:lang="ru"><surname>Головина</surname><given-names>А. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Anastasia A. Golovina.</p><p>1 Universitetskaya pl., Voronezh 394018</p></bio><bio xml:lang="ru"><p>394018 Воронеж, Университетская пл., 1</p></bio><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Voronezh State University</institution></aff><aff><institution xml:lang="ru">ФГБОУ ВО «Воронежский государственный университет»</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2025-07-15" publication-format="electronic"><day>15</day><month>07</month><year>2025</year></pub-date><volume>24</volume><issue>2</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>56</fpage><lpage>65</lpage><history><date date-type="received" iso-8601-date="2025-07-15"><day>15</day><month>07</month><year>2025</year></date><date date-type="accepted" iso-8601-date="2025-07-15"><day>15</day><month>07</month><year>2025</year></date></history><permissions><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/></permissions><self-uri xlink:href="https://bioterapevt.abvpress.ru/jour/article/view/1553">https://bioterapevt.abvpress.ru/jour/article/view/1553</self-uri><abstract xml:lang="en"><p><bold>Background</bold>. Currently, various approaches can be used to increase the solubility and dissolution rate of poorly water-soluble pharmaceutical substances, such as salt formation, solubilization with co-solvents, particle size reduction, or preparation of solid dispersions. A promising and relevant area in pharmaceutical science is the production of solid dispersions. Polyvinylpyrrolidone and polyethyleneglycols of various molecular weights are most often used as carrier polymers in the production of solid dispersions.</p><p><bold>Aim</bold>. Analysis of desloratadine solid dispersions by physicochemical and thermal methods in order to substantiate the most optimal composition and technology for obtaining solid dispersions.</p><p><bold>Materials and methods</bold>. Solid dispersions of desloratadine with polyethyleneglycol-1500, polyethyleneglycol-4000, polyethyleneglycol-6000, polyvinylpyrrolidone-10000 as carriers in the ratios of 1:1, 1:2, 1:5 were used as objects of study. To determine the morphological features of the obtained samples, scanning electron microscopy was used on a JSM-6380LV device (JEOL, Japan). IR spectroscopy was performed on a Vertex-70 device (Bruker Optik GmbH, Germany), in the mid-IR region of 4000–400 cm<sup>–1</sup> using the total internal reflection method. In order to study the crystal structure of solid dispersions with polymer carriers, X-ray phase analysis was performed using the powder X-ray diffractometry method on a DRON device. Studies by the differential scanning calorimetry (DSC) method were carried out on a synchronous thermal analysis device model STA 449 F3 (Netzsch, Germany).</p><p><bold>Results</bold>. IR spectra of desloratadine solid dispersions demonstrated fluctuations in the areas corresponding to the functional groups of the pharmaceutical substance and polymers. The X-ray diffraction pattern of samples of desloratadine solid dispersions with polymers shows a loss of the crystalline structure of the pharmaceutical substance. when conducting differential scanning calorimetry, the lowest value of specific heat of complexation was found for solid dispersions of desloratadine with polyethyleneglycol –1500 and polyethyleneglycol –6000.</p><p><bold>Conclusion</bold>. The conducted studies showed that the optimal polymer for obtaining solid dispersions is polyethyleneglycol-1500.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Введение</bold>. В настоящее время для повышения растворимости и скорости растворения плохо растворимых в воде фармацевтических субстанций возможно использовать различные подходы, такие как образование солей, солюбилизация сорастворителями, уменьшение размера частиц или приготовление твердых дисперсий. Перспективным и актуальным направлением в фармацевтической науке представляется получение твердых дисперсий. В качестве полимеров-носителей при производстве твердых дисперсий чаще всего используют поливинилпирролидон и полиэтиленгликоли различной молекулярной массы.</p><p><bold>Цель исследования</bold> – анализ твердых дисперсий дезлоратадина физико-химическими и термическим методами для обоснования оптимального состава и технологии получения твердых дисперсий.</p><p><bold>Материалы и методы</bold>. В качестве объектов исследования использованы твердые дисперсии дезлоратадина с полиэтиленгликолем-1500, полиэтиленгликолем-4000, полиэтиленгликолем-6000, поливинилпирролидоном-10000 в качестве носителей в соотношениях 1:1, 1:2, 1:5. Для определения морфологических особенностей полученных образцов использовали растровую электронную микроскопию на приборе JSM-6380LV (JEOL, Япония). Инфракрасную (ИК) спектроскопию проводили на приборе Vertex-70 (Bruker Optik GmbH, Германия), в средней ИК-области в диапазоне 4000–400 см<sup>–1</sup> методом нарушенного полного внутреннего отражения. С целью изучения кристаллической структуры твердых дисперсий с полимерными носителями проводили рентгенофазный анализ методом порошковой рентгеновской дифрактометрии на приборе типа «ДРОН». Исследования методом дифференциальной сканирующей калориметрии осуществляли на приборе синхронного термического анализа модели STA 449 F3 (Netzsch, Германия).</p><p><bold>Результаты</bold>. ИК-спектры твердых дисперсий дезлоратадина продемонстрировали колебания в областях, соответствующих функциональным группам фармацевтической субстанции и полимерам. На рентген-дифрактограмме образцов твердых дисперсий дезлоратадина с полимерами наблюдается потеря фармацевтической субстанцией кристаллической структуры. При проведении дифференциальной сканирующей калориметрии установлено наименьшее значение удельной теплоты комплексообразования у твердых дисперсий дезлоратадина с полиэтиленгликолем-1500 и полиэтиленгликолем-6000.</p><p><bold>Заключение</bold>. Оптимальным полимером для получения твердых дисперсий является полиэтиленгликоль-1500.</p></trans-abstract><kwd-group xml:lang="en"><kwd>solid dispersions</kwd><kwd>desloratadine</kwd><kwd>infrared spectroscopy</kwd><kwd>X-ray phase analysis</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>твердые дисперсии</kwd><kwd>дезлоратадин</kwd><kwd>инфракрасная спектроскопия</kwd><kwd>рентгенофазный анализ</kwd></kwd-group><funding-group><funding-statement xml:lang="en">This work was supported by the Russian Science Foundation (Grant No. 24-25-20015), https://rscf.ru/en/project/24-25-20015/.</funding-statement><funding-statement xml:lang="ru">Исследование выполнено за счет гранта Российского научного фонда № 24-25-20015, https://rscf.ru/project/24-25-20015/.</funding-statement></funding-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Shi Z., Wang C., Sun C.C. Molecular origin of the distinct tabletability of loratadine and desloratadine: role of the bonding area – bonding strength interplay. Pharm Res 2020;37(7):133. DOI: 10.1007/s11095-020-02856-2</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Wen Y., Tang Y., Li M., Lai Y. Efficiency and safety of desloratadine in combination with compound glycyrrhizin in the treatment of chronic urticaria: a meta-analysis and systematic review of randomised controlled trials. Pharm Biol 2021;59(1):1276–85. DOI: 10.1080/13880209.2021.1973039</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>González-Núñez V., Valero A., Mullol J. Safety evaluation of desloratadine in allergic rhinitis. Expert Opin Drug Saf 2013;12(3):445–53. DOI: 10.1517/14740338.2013.788148</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>DuBuske L.M. Review of desloratadine for the treatment of allergic rhinitis, chronic idiopathic urticaria and allergic inflammatory disorders. Expert Opin Pharmacother 2005;6:2511–23. DOI: 10.1517/14656566.6.14.2511</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Li F., Xu Q., Zhu Q. et al. Design, synthesis and biological evaluation of novel desloratadine derivatives with anti-inflammatory and H(1) antagonize activities. Bioorg Med Chem Lett 2019;29(24):126712. DOI: 10.1016/j.bmcl.2019.126712</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Bernstein J.A., Bernstein J.S., Makol R., Ward S. Allergic rhinitis: a review. JAMA 2024;331(10):866–77. DOI: 10.1001/jama.2024.0530</mixed-citation></ref><ref id="B7"><label>7.</label><citation-alternatives><mixed-citation xml:lang="en">The State Pharmacopoeia of the Russian Federation XV. URL: https://pharmacopoeia.regmed.ru/pharmacopoeia/izdanie-15/ (In Russ.).</mixed-citation><mixed-citation xml:lang="ru">Государственная фармакопея РФ XV. URL: https://pharmacopoeia.regmed.ru/pharmacopoeia/izdanie-15/</mixed-citation></citation-alternatives></ref><ref id="B8"><label>8.</label><mixed-citation>Berginc K., Sibinovska N., Žakelj S. et al. Biopharmaceutical classification of desloratadine – not all drugs are classified the easy way. Acta Pharm 2020;70(2):131–44. DOI: 10.2478/acph-2020-0006</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Ali S.M., Upadhyay S.K., Maheshwari A. NMR spectroscopic study of the inclusion complex of desloratadine with β-cyclodextrin in solution. J Incl Phenom Macrocycl Chem 2007;59:351–5. DOI: 10.1007/s10847-007-9335-y</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Barea S.A., Mattos C.B., Cruz A.C. et al. Solid dispersions enhance solubility, dissolution, and permeability of thalidomide. Drug Dev Ind Pharm 2017;43(3):511–8. DOI: 10.1080/03639045.2016.1268152</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Liu X., Zhang Z., Jiang Y. et al. Novel PEG-grafted nanostructured lipid carrier for systematic delivery of a poorly soluble antileukemia agent Tamibarotene: characterization and evaluation. Drug Deliv 2015;22(2):223–9. DOI: 10.3109/10717544.2014.885614</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Huang B.B., Liu D.X., Liu D.K., Wu G. Application of solid dispersion technique to improve solubility and sustain release of emamectin benzoate. Molecules 2019;24(23):4315. DOI: 10.3390/molecules24234315</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Polkovnikova Yu.A., Glizhova T.N., Arutyunova N.V., Sokulskaya N.N. PEG-4000 increases solubility and dissolution rate of vinpocetin in solid dispersion system. Chimica Techno Acta 2022;9(S):202292S11. DOI: 10.15826/chimtech.2022.9.2.S11</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Ben Osman Y., Liavitskaya T., Vyazovkin S. Polyvinylpyrrolidone affects thermal stability of drugs in solid dispersions. Int J Pharm 2018;551(1-2):111–20. DOI: 10.1016/j.ijpharm.2018.09.020</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Andrews G.P., AbuDiak O.A., Jones D.S. Physicochemical characterization of hot melt extruded bicalutamide-polyvinylpyrrolidone solid dispersions. J Pharm Sci 2010;99(3):1322–35. DOI: 10.1002/jps.21914</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Le Khanh H.P., Haimhoffer Á., Nemes D. et al. Effect of molecular weight on the dissolution profiles of peg solid dispersions containing ketoprofen. Polymers 2023;15(7):1758. DOI: 10.3390/polym15071758</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Bolourchian N., Mahboobian M.M., Dadashzadeh S. The effect of PEG molecular weights on dissolution behavior of simvastatin in solid dispersions. Iran J Pharm Res 2013;12: 11–20. PMID: 24250667</mixed-citation></ref><ref id="B18"><label>18.</label><citation-alternatives><mixed-citation xml:lang="en">Krasnyuk (Jr) I.I., Beliatskaya A.V., Krasnyuk I.I. et al. Effect of polymers on the physical and chemical properties of benzonal in solid dispersions. Vestnik Moskovskogo universiteta = Bulletin of the Moscow University. Series 2: Chemistry 2021;62(1):44–8. (In Russ.).</mixed-citation><mixed-citation xml:lang="ru">Краснюк (мл.) И.И., Беляцкая А.В., Краснюк И.И. и др. Влияние полимеров на физико-химические свойства бензонала в твердых дисперсиях. Вестник Московского университета. Серия 2: Химия 2021;62(1):44–8.</mixed-citation></citation-alternatives></ref><ref id="B19"><label>19.</label><mixed-citation>Jelić D. Thermal stability of amorphous solid dispersions. Molecules 2021;26(1):238. DOI: 10.3390/molecules26010238</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Tran T.T.D, Tran P.H.L. Molecular interactions in solid dispersions of poorly water-soluble drugs. Pharmaceutics 2020;12(8):745. DOI: 10.3390/pharmaceutics12080745</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Park C., Meghani N., Loebenberg R. et al. Fatty acid chain length impacts nanonizing capacity of albumin-fatty acid nanomicelles: Enhanced physicochemical property and cellular delivery of poorly water-soluble drug. Eur J Pharm Biopharm 2020;152:257–69. DOI: 10.1016/j.ejpb.2020.05.011</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Tran T.T.D., Tran P.H.-L., Lim J. et al. Physicochemical principles of controlled release solid dispersion containing a poorly water-soluble drug. Ther Deliv 2010;1:51–62. DOI: 10.4155/tde.10.3</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Sarabu S., Kallakunta V.R., Bandari S. et al. Hypromellose acetate succinate based amorphous solid dispersions via hot melt extrusion: effect of drug physicochemical properties. Carbohydr Polym 2020;233:115828. DOI: 10.1016/j.carbpol.2020.115828</mixed-citation></ref><ref id="B24"><label>24.</label><citation-alternatives><mixed-citation xml:lang="en">Polkovnikova Yu.A., Kоryanova K.N., Vasilevskaya E.S. The effect of solid dispersions with PEG-1500 on the release of vinpocetine. Biofarmatsevticheskiy zhurnal = Biopharmaceutical Journal 2019;11(5):69–76. (In Russ.).</mixed-citation><mixed-citation xml:lang="ru">Полковникова Ю.А., Корянова К.Н., Василевская Е.С. Влияние твердых дисперсий с ПЭГ-1500 на характер высвобождения винпоцетина. Биофармацевтический журнал 2019;11(5):69–76.</mixed-citation></citation-alternatives></ref><ref id="B25"><label>25.</label><mixed-citation>Polkovnikova Yu.A., Severinova N.A., Koryanova K.N. et al. Morphological, technological and biopharmaceutical studies of alginate-chitosan microcapsules with vinpocetine. Pharmacy &amp; Pharmacology 2019;7(5):279–90. DOI: 110.19163/2307-9266-2019-7-5-279-290</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Polkovnikova Yu.A., Chistyakova V.M. Physicochemical and biopharmaceutical studies of solid dispersions of cinnarizine. Pharmaceutical Chemistry Journal 2023;57(3):424–9. DOI: 10.30906/0023-1134-2023-57-3-45-49</mixed-citation></ref></ref-list></back></article>
